Use in one member state might be enough – CJEU rules in Onel case

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Use in one member state might be enough – CJEU rules in Onel case

Territorial borders between EU member states should be disregarded in assessing whether a CTM has been put to genuine use in the Community, the Court of Justice of the EU said today in its long-awaited ruling in the Onel case

Instead, said the Court, national courts must consider the characteristics of the market concerned, the nature of the goods or services protected by the trade mark and the territorial extent and the scale of the use as well as its frequency and regularity.

The CJEU was asked to rule in the case which concerned essentially whether a Community trade mark (CTM) that had been put to genuine use in just one member state met the standard required in the EU Trade Mark Regulation.

The question has provoked controversy as accepted wisdom had always been that use in just one of the 27 EU member states should be sufficient to maintain a trade mark. But many practitioners have criticised that position, saying it is not practical in an EU that consists of 27 diverse countries, and leads to the CTM register being overcrowded.

In its judgment today, the Court acknowledged the difficulties raised by the various arguments, but was unable to fully resolve them.

It did say that, in certain circumstances, the market for the goods or services for which a CTM has been registered is restricted to the territory of a single state: “In such a case, use of the Community trade mark on that territory might satisfy the conditions both for genuine use of a Community trade mark and for genuine use of a national trade mark.” But it did not elaborate on the circumstances when this might be the case.

Moreover, the Court declined to lay down a de minimis rule. It said that, as the assessment of genuine use must consider all the relevant facts and circumstances, “it is impossible to determine a priori, and in the abstract, what territorial scope should be chosen in order to determine whether the use of the mark is genuine or not”.

Turning to the facts of the Onel v Omel case, the Court appeared to throw up its hands, saying it did not have “the factual information necessary” to provide “more specific guidance” to the national court.

However it did reject arguments stemming from cases such as General Motors and Pago International, as it said these concerned protection for trade marks with a reputation or that are well known, adding that “the requirement for genuine use, which could result in an opposition being rejected or even in the trade mark being revoked ... pursues a different objective from those provisions”.

more from across site and SHARED ros bottom lb

More from across our site

The Texas-based IP litigation hires take King & Spalding’s partner appointments from pre-merger Winston & Strawn up to 12 this year
Sunny Su explains how her team overcame challenges with orchard evidence collection to secure a favourable plant variety decision from China’s top court
Flexible working firm continues trajectory from 2025 with appointment of Matthew Grant and Letao Qin
Anousha Davies, associate and trademark attorney at Birketts, unpicks how the university’s reputation enabled it to see off a proposed trademark for ‘Cambridge Rowing’
IP lawyers, who say they are encouraging clients to build up ‘tariff resilience’, should treat the risks posed by recent orders as a core consideration in cross-border licensing
Regulatory changes and damages risks are prompting Canadian firms and clients to opt for settlements in generic and biosimilar cases
News of Via Licensing Alliance adding two new members and Nokia’s proposal to extend interim licences to Warner Bros Discovery and Paramount were also among the top talking points
A new claim filed by Ericsson, and a request for access to documents, were also among recent developments
Cooley and Stikeman Elliott advised 35Pharma on the deal, which will allow GSK to get its hands on S235, an investigational medicine for pulmonary hypertension
Simon Wright explains why the UK should embrace the possibility of rejoining the UPC, and reveals how CIPA is reacting to this month’s historic Emotional Perception AI case at the UK Supreme Court
Gift this article